Aug 11, 2020 / 02:55PM GMT
Vasiliana Vireen Moussatos - Wedbush Securities Inc., Research Division - MD of Equity Research
Thank you very much for joining us at the 2020 Virtual Wedbush Healthcare Conference. My name is Liana Moussatos, and I'm one of the senior health care analysts at Wedbush. It's my pleasure to introduce our next presenting company, BioMarin Pharmaceuticals, which is on the Wedbush's Best Ideas List. BioMarin is the first company to develop a one-shot-and-done gene therapy cure for hemophilia A and is years ahead of the competition.
Today, we are joined by the CFO, Brian Mueller; and Chief Commercial Officer, Jeff Ajer. Thanks very much for joining us. We will start with a fireside chat and then transition to Q&A. If you would like to ask a question, please submit them through the chat window at the bottom of your screen.
Questions and Answers:
Vasiliana Vireen Moussatos - Wedbush Securities Inc., Research Division - MD of Equity ResearchSo Brian, Jeff, let's start with ROCTAVIAN for hemophilia A. Can you describe the burden of the disease? And
Trustpilot
